Intravenous and inhalational colistininduced respiratory failure

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages

  Wahby, Krista ^a   Chopra, Teena ^a   Chandrasekar, Pranatharthi ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; HYDROMORPHONE; LINEZOLID; METHYLPREDNISOLONE; SULTAMICILLIN; VORICONAZOLE; ANTIINFECTIVE AGENT; COLISTIN;

ACINETOBACTER INFECTION; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; HYPOTENSION; MALAISE; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; STAPHYLOCOCCAL PNEUMONIA; SYMPTOM; ACINETOBACTER BAUMANNII; CHEMICALLY INDUCED DISORDER; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; PNEUMONIA, BACTERIAL; RESPIRATORY INSUFFICIENCY;

EID: 77749292059     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650582     Document Type: Article

References (15)

1. Falagas ME, Kasiakou SK. Toxicity of polymyxins; a systematic review of the evidence from old and recent studies. Crit Care 2006; 10(1):R27.
2. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral Colistin for the treatment of serious infections due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37(1):e154-e160.
3. Linden PK, Paterson DL. Parenteral and inhaled Colistin for treatment of ventilator-assiciated pneumonia. Clin Infect Dis 2006;43(Suppl 2):S89-94.
4. Falagas ME, Kasiakou SF, Tsiodras S, Michalopoulas A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature. Clin Med Res 2006; 4(2):138-146. (Pubitemid 44047368)
5. Pintado V, San Miguel L, Grill F, et al. Intravenous Colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56:185-190.
6. US Food and Drug Administration. FDA Alert 6/28/2007. MedWatch Online. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm.
7. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:857-868.
8. Coly-Mycin M parenteral (Sterile colistimethate sodium, USP [package insert]). Bristol, TN: Monarch Pharmaceuticals, 2006.
9. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and Colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacthera 1999; 33:960-967.
10. Vanhaeverbeek M, Ectors M, Vanhaelst L, Franken L. Myopathy caused by polymixin E: functional disorder of the cell membrane. J Neurol Neurosurg Psychiatry 1974; 37:1343-1345.
11. Duncan DA. Colistin toxicity: neuromuscular and renal manifestations. Minn Med 1973; 56:31-35.
12. Lindesmith LA, Baines D, Bigelow B, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Int Med 1968; 68(2):318-327.
13. Falagas ME, Rafailidis PI. Nephrotoxicity of Colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48:1729-1731.
14. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of Colistin in cystic fibrosis patients. DICP 1991; 25:1168-1170
15. Dickie KJ, deGroot WJ. Ventilatory effects of aerosolized kanamycin and polymyxin. Chest 1973; 63(5):694-697.